Lv1
12 积分 2021-07-14 加入
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
12分钟前
待确认
Delayed insulin secretion response during an OGTT is associated with an increased risk for incidence of diabetes in NGT subjects
3个月前
已完结
Issues in Using Progression-Free Survival When Evaluating Oncology Products
3个月前
已完结
Surrogate End Points in Clinical Trials: Are We Being Misled?
5个月前
已完结
The Validation of Surrogate End Points by using Data from Randomized Clinical Trials: A Case-Study in Advanced Colorectal Cancer
5个月前
已完结
Surrogate endpoints for overall survival in lung cancer trials: a review
5个月前
已完结
Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?
5个月前
已完结
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
6个月前
已完结
Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
6个月前
已完结
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop
6个月前
已完结
皖公网安备34019202002308
